V
VERASTEM INC
NASDAQ: VSTM (Verastem, Inc.)
Last update: 1 hour ago9.38
-0.47 (-4.77%)
| Previous Close | 9.85 |
| Volume | 3,023,993 |
| Price / Sales | 10.01 |
| Price / Book | 17.85 |
| 52 Weeks Range |
| Operating Margin (TTM) | -1,310.71% |
| Diluted EPS (TTM) | -3.36 |
| Total Debt/Equity (MRQ) | 128.59% |
| Current Ratio (MRQ) | 3.50 |
| Operating Cash Flow (TTM) | -115.14 M |
| Levered Free Cash Flow (TTM) | -67.89 M |
| Return on Assets (TTM) | -64.19% |
| Return on Equity (TTM) | -2,159.52% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Verastem, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Relative Valuation | NA |
| Financial Health | -1.6 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.75 |
Select this tab to load the latest available analysis.
|
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.93% |
| % Held by Institutions | 78.87% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Armistice Capital, Llc | 30 Jun 2026 | 7,024,000 |
| Rtw Investments, Lp | 30 Jun 2026 | 6,635,793 |
| Deep Track Capital, Lp | 30 Jun 2026 | 5,740,850 |
| Rosalind Advisors, Inc. | 30 Jun 2026 | 3,986,509 |
| Foresite Capital Management Vi Llc | 30 Jun 2026 | 3,146,631 |
| Baker Bros. Advisors Lp | 30 Jun 2026 | 2,499,338 |
| Alyeska Investment Group, L.P. | 30 Jun 2026 | 2,289,625 |
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |